Pharming Group (NASDAQ:PHAR - Get Free Report) fell 2% during mid-day trading on Monday . The stock traded as low as $8.58 and last traded at $8.75. 5,512 shares traded hands during trading, a decline of 11% from the average session volume of 6,201 shares. The stock had previously closed at $8.93.
Analyst Upgrades and Downgrades
PHAR has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer lifted their price target on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. Finally, Jefferies Financial Group assumed coverage on Pharming Group in a research report on Monday, December 9th. They issued a "buy" rating and a $14.00 price objective for the company.
Read Our Latest Research Report on PHAR
Pharming Group Stock Up 0.4 %
The firm has a market cap of $590.78 million, a P/E ratio of -33.40 and a beta of -0.10. The firm's fifty day moving average is $8.83 and its 200 day moving average is $8.65. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). The firm had revenue of $92.70 million for the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts anticipate that Pharming Group will post -0.2 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by hedge funds and other institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
